Comprehensive and reliable antibody and immune monitoring solution in the fight against COVID-19
Features of Neutralizing Antibodies (NAb) Testing:
• Assesses multiple antibody types against multiple SARS-CoV-2 antigens
• Holds a high sensitivity profile has 10 measures for a complete picture
of an individual’s immune response*
• Detects the level of antibodies from either a natural infection or a vaccine
• Allows for Workforce monitoring for COVID-19 antigens is highly effective
• Provides a 30/60/90 day look back AND forward as a predictor of
effectiveness against future variants
• Saves a business both time and money with less frequent
COVID-19 PCR testing
• Helps Keep employees safer by identifying those employees most at risk
• Know which antibodies are present provides actionable advice to base
business decisions and individual health decisions upon
• Help business populations or travelers know their risk(s) of exposure
• Provides actionable advice and if/when additional precautions are warranted**
• Can minimize lost time and wages for employees with less frequent quarantines
• Physician Telehealth consultation included with Hermes Health Sciences
for interpretation of NAb testing
Identification of a correlate of protection against infection has been a challenge
despite publication of compelling models and data that have argued for methodologies
that can correlate certain immune parameters with protection against COVID-19.1 While immune responses to an infectious agent are undeniably complex and multifactorial and include contributions from the innate immune response and adaptive immune response (humoral and cellular), evidence suggests that neutralizing antibodies (NAb) play an important protective role. 2-4 For instance,
T cell recognition is a crucial early event for development of an immune response to a viral infection. Once an individual has been exposed through natural infection or vaccination, T and B memory cells develop and expand to protect the host in case of future exposures to the virus. Presence of these memory cells can significantly reduce symptoms associated with re- infections as they shorten the time needed to ramp up antibody production. Furthermore, low levels of antibodies may continue to be present, which may prevent severe if not symptomatic disease.1
Many of the currently available COVID-19 vaccines, including the mRNA vaccines widely provided in U.S. and other countries, encode for the spike protein. The spike protein harbors the receptor-binding domain (RBD) of SARS-CoV-2 that is used by the virus for binding to the ACE-2 receptor on human cells to allow the virus to enter and hijack the cell to do what it does:
replicate and move on to other cells. NAb bind and prevent the interaction between RBD and ACE-2 thereby preventing viral entry into the cell. In this context, levels of NAb may be a relevant measure of the effectiveness of the immune response in preventing infection of cells by SARS-CoV-2.
Single and workforce monitoring testing or concierge testing for onsite, home, or event locations are all available. Allow Hermes Health Sciences to formulate an effective program for your needs.
1 Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nature Medicine, https://doi.org/10.1038/s41591-021- 01377-8 (2021).
2-4 Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science 369, 956–963 (2020). 3. McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630–634 (2021). 4. Regeneron Reports Positive Interim Data with REGEN-COVTM Antibody Cocktail used as Passive Vaccine to Prevent COVID-19 (Regeneron press release, 26 January 2021). https://newsroom. regeneron.com/news-releases/news-releasedetails/regeneronreports positive-interim-data-regen-covtm-antibody (2021).